Description
SK-N-MC was originally described as a neuroblastoma cell line. It is now widely regarded as having originated from an Askin’s tumor (Ewing family of tumors). These cells harbor the oncogenic EWS-FLI1 chromosomal rearrangement. They were initially found to contain double-minute chromosomes, which were lost upon prolonged in vitro culture. The SK-N-MC cells have little or no dopamine-b-hydroxylase activity but show elevated choline acetyltransferase activity compared to other neuroblastoma cell lines such as the SK-N-SH and SH-SY5Y. These cells are known to form tumors in immunocompromised mice.
Source
This cell line was established in 1971 from a metastatic site (supra-orbital region) in a 14-year-old Caucasian female with an Askin’s tumor.
Inventors
- June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
- Lawrence Helson, MD, formerly at Memorial Sloan Kettering
- Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
Key References
- Biedler JL et al. (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Research 33: 2643-2652 (PubMed ID: 4748425)
- Helson L et al. (1975) Human neuroblastoma in nude mice. Cancer Research 35: 2594-2599 (PubMed ID: 167965)
- Biedler JL et al. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Research 38: 3751-3757 (PubMed ID: 29704)
Licensing Information
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at bugaa@mskcc.org. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact Alexandra Buga, MS, MBA, Licensing Manager, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org.